Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CL-P24113a is a dietary supplement formulated as a blend of **botanical and well-established compounds** targeting the management of **androgenetic alopecia (AGA)** in men. The formulation includes the following active ingredients: *Pumpkin Seed Oil (Curcubita pepo), Saw Palmetto Oil (Serenoa repens), L-Cystine, Prunus africana Bark Extract (Pygeum africanum), Horsetail Extract (Equisetum arvense), Olive Leaf Extract*, and other excipients. The supplement is administered orally, once daily, and is being evaluated in a clinical study for its efficacy and safety in improving hair growth and density among males with mild to moderate AGA (Hamilton-Norwood stages II–IV)[1]. The study utilizes both instrumental (e.g., TrichoScan HD) and subjective assessments to monitor outcomes over a 6-month treatment course[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CL-P24113a.